Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05245500 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

A Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
336
Enrollment target
20
Study locations

NCT05245500 is a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 336 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05245500, a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
336 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Conditions Studied

Non-Small Cell Lung Cancer Solid Tumor Advanced Solid Tumor Pancreatic Adenocarcinoma Mesothelioma Malignant Peripheral Nerve Sheath Tumors

Interventions

  • DRUG MRTX1719

Study Locations (20)

New York

  • Local Institution - 129 - Mineola
  • David H Koch, Memorial Sloan Kettering Cancer Center - New York
  • New york cancer and blood specialists - Oncology - Port Jefferson Station
  • New york cancer and blood specialists - Oncology - Port Jefferson Station

Texas

  • Ut Southwestern - Dallas
  • Texas Oncology - DFW - Fort Worth
  • MDACC - Houston

Colorado

  • Sarah Cannon Research Institute (SCRI) - HealthONE Location - Denver
  • Rocky Mountain Cancer Centers, LLP - Oncology - Lone Tree

Florida

  • Mayo Clinic - Jacksonville
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando

North Carolina

  • University of North Carolina - Gastroenterology and Hepatology - Chapel Hill
  • University of North Carolina - Chapel Hill

Arizona

  • Mayo Clinic - Phoenix

Illinois

  • Local Institution - 124 - Chicago

Massachusetts

  • Dana-Farber Cancer Institute - Brookline

Trial Details

FieldValue
Enrollment Target 336 participants
Start Date 2022-06-09
Est. Completion 2027-12-10
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05245500

The ClinicalTrials.gov registry entry for NCT05245500 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (49% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRTX1719 is the first listed.

NCT05245500 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, Texas, Colorado.

Frequently Asked Questions

What is clinical trial NCT05245500 about?

NCT05245500 is a clinical study titled "Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion". This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

What is the current status of trial NCT05245500?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 336 participants. The study started on 2022-06-09. Estimated completion is 2027-12-10.

What conditions does trial NCT05245500 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Advanced Solid Tumor, Pancreatic Adenocarcinoma, Mesothelioma.

What interventions are being tested in trial NCT05245500?

The interventions under investigation include: MRTX1719 (DRUG).

Who is sponsoring clinical trial NCT05245500?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05245500 being conducted?

This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.